Related Experiment Video
Updated: Jan 19, 2026
Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
Published on: March 31, 2023
Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics
Saketh S Dinavahi1, Christopher G Bazewicz2, Raghavendra Gowda3
1Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; Penn State Melanoma and Skin Cancer Center, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Abstract:
Aldehyde dehydrogenases (ALDHs) are highly expressed in the chemotherapy- and radiotherapy-resistant cell subpopulations of many different cancer types. Accordingly, the development of ALDH inhibitors may be the most direct approach to target these cell populations. However, inhibiting multiple ALDH family members can be toxic and isoform-specific inhibition is often ineffective. This review discusses the role of ALDH in cancer and therapy resistance, and then overviews the various available ALDH inhibitors with a focus on the clinical potential and limitations of these agents as cancer therapeutics. Finally, challenges and future research directions to effectively target ALDH in the management of cancer therapy resistance are discussed.
Insights
Aldehyde dehydrogenases (ALDHs) drive cancer therapy resistance. Targeting ALDHs may overcome resistance, but challenges like toxicity and effectiveness require further research for better cancer treatments.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Aldehyde dehydrogenases (ALDHs) are highly expressed in cancer cells resistant to chemotherapy and radiotherapy.
- Targeting ALDHs presents a direct strategy to eliminate these resistant cancer cell populations.
Purpose of the Study:
- To review the role of ALDH in cancer and therapy resistance.
- To overview ALDH inhibitors, focusing on their clinical potential and limitations.
- To discuss future research directions for targeting ALDH in cancer therapy resistance.
Main Methods:
- Literature review of ALDH function in cancer.
- Analysis of existing ALDH inhibitors and their therapeutic applications.
- Discussion of challenges and future research in ALDH inhibition for cancer therapy.
Main Results:
- ALDHs are implicated in resistance to various cancer therapies.
- Current ALDH inhibitors face challenges including toxicity and isoform-specific efficacy.
- Targeting ALDH remains a promising but complex therapeutic strategy.
Conclusions:
- Effective targeting of ALDH in cancer therapy requires overcoming isoform-specific inhibition challenges.
- Further research is needed to develop safe and effective ALDH inhibitors for clinical use.
- Optimizing ALDH inhibition strategies is crucial for managing cancer therapy resistance.
Related Concept Videos
09:59Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
11:44Isolation of Stem Cells from Human Pancreatic Cancer Xenografts
07:46In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
08:36Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
09:243-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research